Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Cancer therapy developer Orca Bio hopes to turn fresh results from a late-stage clinical trial into regulatory approval next ...

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

Researchers in China have used the body’s own immune system to kill cancerous cells in a pioneering new therapy.

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

A 68-year-old man with prostate cancer develops penile metastases, a rare but serious complication, reinforcing the need for ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to ...